Please login to the form below

Not currently logged in
Email:
Password:

neuroscience

This page shows the latest neuroscience news and features for those working in and with pharma, biotech and healthcare.

Merck & Co signs deal with Amathus for neurodegeneration diseases

Merck & Co signs deal with Amathus for neurodegeneration diseases

The Merck neuroscience team is an ideal partner to translate this novel approach into potential first-in-class, disease modifying treatments for patients with neurodegenerative diseases,” he added.

Latest news

More from news
Approximately 13 fully matching, plus 180 partially matching documents found.

Latest Intelligence

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    MindMaze, the Swiss start-up which entered the unicorn club in 2016, works at the intersection of neuroscience, mixed reality and artificial intelligence and builds intuitive human machine interfaces for different

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinson’s disease

    The reactions to Pfizer dropping neuroscience research ranged from ‘disappointing’ to ‘demoralising’.The move was compounded by the company saying the decision was driven by science rather than cost, a shockwave ... It’s snakes and ladders.

  • AI and genomics: a revolution in drug discovery and development AI and genomics: a revolution in drug discovery and development

    Ten of the new ALS-related genes are being tested using an existing neural progenitor cell assay at the Sheffield Institute for Translational Neuroscience (SITraN).

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    In 2018, venture capitalists invested almost $1.5bn (1.4bn) in neuroscience biotechs, an increase of more than 500% over funding levels in 2011. ... Dave Reese, head of R&D at Amgen, touched on those issues to explain Amgen’s exit from neuroscience

  • The changing nature of approvals – what does the future hold? The changing nature of approvals – what does the future hold?

    the phases of development represented in the analysis and, until the recent about-turn by Biogen, the outlook for neuroscience was bleak. ... Therapeutically, oncology and rare diseases will likely remain attractive candidates for investment, while

More from intelligence
Approximately 2 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 44 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 8 fully matching, plus 22 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics